MaaT Pharma
Quick facts
Phase 3 pipeline
- MaaT013 · Immunology / Gastroenterology
MaaT013 is a microbiota-based therapeutic that restores a healthy gut microbiome composition to treat immune-mediated diseases.
Phase 2 pipeline
- Autologous Fecal Microbiota Transplantation · Gastroenterology
Autologous Fecal Microbiota Transplantation involves transplanting a patient's own fecal microbiota to restore a balanced gut microbiome. - fecal microbiota transfer
- Pooled allogeneic fecal microbiotherapy
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: